Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

In vivo Alzheimer's disease diagnosis and staging is traditionally based on clinical features.
However, the agreement between clinical and pathological Alzheimer's disease diagnosis …

Abstract Positron Emission Tomography (PET) ligands have advanced Alzheimer's disease
(AD) diagnosis and treatment. Using autoradiography and cryo-EM, we identify AD brain …

Brain inflammation, with an increased density of microglia and macrophages, is an important
component of Alzheimer's disease and a potential therapeutic target. However, it is …

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases among
the older population. Its main pathological features include the abnormal deposition of …

From Alzheimer's disease to amyotrophic lateral sclerosis, the molecular cascades
underlying neurodegenerative disorders remain poorly understood. The clinical view of …

Alzheimer's disease is the most common cause of dementia in the elderly, prompting
extensive efforts to pinpoint novel therapeutic targets for effective intervention. Among the …

Background Blood-based disease staging across the Alzheimer's disease (AD) continuum
holds the promise to identify individuals that profit from disease-modifying therapies. We set …

The glymphatic system is considered to play a pivotal role in the clearance of disease-
causing proteins in neurodegenerative diseases. This study employed MR diffusion tensor …

In Alzheimer's disease (AD), neuropsychiatric symptoms (NPS) correlate with tau deposition
in the brain. Here, we investigated the association of PET-based Braak stages with NPS and …